Mifobate

Research use only, not for human use.

Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects.

Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects[1].SR-202 is a new synthetic PPARgamma antagonist,which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor. In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation[1].In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. These effects are accompanied by a smaller size of the adipocytes and a reduction of TNFalpha and leptin secretion. Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice.

——

Animal Model:Eight-week-old male ob/ob mice Dosage:400 mg/kg Administration:Feed (food admixture maintained for 20 days)Result:Prevented the time-dependent increase in glucose concentrations.

SR-202

Metabolic Enzyme/Protease

PPAR

PPARγ

——

——

76541-72-5

358.65

C11H17ClO7P2

>98% (HPLC)

H2O:35.87 mg/mL (100.01 mM; Need ultrasonic and warming)

COP(=O)(OC)OC(C1=CC=C(Cl)C=C1)P(=O)(OC)OC

——

(-20℃)

With Ice Pack

≥ 2 years